People: Daxor Corp (DXR)

DXR on American Stock Exchange

6.59USD
24 Oct 2014
Price Change (% chg)

$0.01 (+0.15%)
Prev Close
$6.58
Open
$6.59
Day's High
$6.59
Day's Low
$6.57
Volume
1,300
Avg. Vol
3,089
52-wk High
$8.90
52-wk Low
$5.65

Search Stocks

Summary

Name Age Since Current Position

Joseph Feldschuh

77 1974 Chairman of the Board, President

James Lombard

78 1989 Independent Director

Bernhard Saxe

74 2012 Independent Director

Robert Willens

65 2002 Independent Director

Martin Wolpoff

70 1989 Independent Director

Diane Meegan

2012 IR Contact Officer

Biographies

Name Description

Joseph Feldschuh

Dr. Joseph Feldschuh, M.D., is Chairman of the Board, President of Daxor Corp. He is on the staff of Montefiore Medical Center. From 1966 to 1983, Dr. Feldschuh was Director of the Cardiac Metabolic Laboratory at Metropolitan Hospital. He has been a Clinical Associate Professor in both medicine and pathology at New York Medical College and an Assistant Clinical Professor at Cornell Medical School. He performed the basic research at the College of Physicians and Surgeons (Columbia University) on the measurement and prediction of normal human blood volume. He is the co-inventor of the BVA-100 Blood Volume Analyzer and the inventor of the quantitative injection kit for the BVA-100. Originally trained in Endocrinology, he is Board Certified in Cardiology and Internal Medicine. Dr. Feldschuh is the Chief Scientist for the Company. He has been personally involved in measuring blood volume on more than 4,000 patients during his medical career. In addition to his duties as Chief Scientist of Daxor, Dr. Feldschuh is also responsible for managing the Company’s investment portfolio.

James Lombard

Mr. James A. Lombard is Independent Director of Daxor Corp. He holds an undergraduate degree in Business Administration (BBA) from Iona College and a Masters Degree (MBA) in Marketing, Banking, and Finance from New York University Graduate School of Business Administration. Mr. Lombard has retired as Director, Administrative Services Division of the City Council of New York and actively participates in civic and community affairs. Prior to joining the City Council, he worked in the banking industry and held various administrative positions with Citicorp and other banks.

Bernhard Saxe

Mr. Bernhard Saxe, Esq., is Independent Director of Daxor Corp. He has been Director since 2008. He is a retired partner in the intellectual property practice group of Foley & Lardner, LLP, and former Vice President of Patent Affairs and Corporate Secretary of Immunomedics, Inc. He is a registered patent attorney and a member of the American Intellectual Property Law Association, American Bar Association and American Chemical Society. He received his J.D. from George Washington University;Ph.D. from Columbia University; and B.A. from Johns Hopkins University in chemistry. Dr. Saxe was named one of the top 10 patent prosecuting attorneys by IP Law and Business, has authored multiple articles pertaining to patent law and given many seminars and lectures on patent law and strategy.

Robert Willens

Mr. Robert Willens is Independent Director of Daxor Corp., Since 2002. He started an independent consulting firm for investors in early 2008 called Robert Willens LLC. Prior to that he was a Managing Director in the Capital Markets department at Lehman Brothers, Inc., in New York where he specialized in tax and accounting issues and in this capacity advised most areas of the firm regarding the optimal structures for corporate capital transactions. He has been instrumental in developing certain financial “products” with a view towards insuring that these products will provide clients with the desired tax and accounting results. Prior to joining Lehman Brothers in 1987, Mr. Willens was a tax partner in the New York office of what was then known as Peat Marwick. Mr. Willens is a prolific author and has written Taxation of Corporate Capital Transactions, as well as over 200 articles for various professional journals. Each year for the past 10 years, Mr. Willens has been named to Institutional Investor’s “All-American Research” Team. Mr. Willens has been selected, on four different occasions, as one of the 100 “Most Influential Accountants” in the United States by Accounting Today . Mr. Willens serves as Adjunct Professor (Finance Department) at Columbia University’s Graduate School of Business where he teaches the course entitled “Investment Banking Tax Factors.”

Martin Wolpoff

Mr. Martin S. Wolpoff is Independent Director of Daxor Corp., Since 1989. He holds B.A., M.A. and M.S. degrees from the City University of New York. He has been active in community affairs since the 1970's. He has served on his local community board for three decades. He served as Chair of the Board for three years and had been Chair of the Health, Hospitals and Social Services; Education; and Libraries Committees. He was elected to his community school board three times, serving as a board member for nine years and as it's President for three. Mr. Wolpoff sat as a member of a Community Development Corporation board for almost 10 years and was a former member of a Health Systems Agency Board, as well as having been a member and Vice-Chair of the Community Advisory Board for a New York City hospital. He was the non-medical member of the Institutional Review Board of a local hospital. He also served as a member of the board of a volunteer ambulance corps. Mr. Wolpoff is retired from the New York City public school system, having served from 1965 to 2002 as an educator, supervisor and administrator. He is currently an educational consultant and has served as an adjunct university professor.

Diane Meegan

Ms. Diane Meegan is IR Contact Officer of Daxor Corporation. Ms. Meegan was Secretary at Daxor Corporation till 2006. Ms. Meegan joined Daxor Corporation in February 2002, as the Senior Executive Assistant to the CEO and President served untill 2002. Ms. Meegan served as the Official Executive Assistant to the CEO of Newbridge Securities, a wholly owned subsidiary of Citigroup, for 13 years. For 4 years, she served as a member of their Problem Review Board. Ms. Meegan also served as the Executive Assistant to the Head of Operations at Instinet Clearing Services. She functions in the capacity of a senior administrative assistant.

Basic Compensation

Name Fiscal Year Total

Joseph Feldschuh

338,406

James Lombard

--

Bernhard Saxe

--

Robert Willens

--

Martin Wolpoff

--

Diane Meegan

--
As Of 30 Dec 2011

Options Compensation

Search Stocks